Society guideline links: Screening for prostate cancer

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Diagnosis and management of prostate cancer".)

International

●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer (2024)

Canada

●Canadian Urological Association (CUA): Recommendations on prostate cancer screening and early diagnosis (2017)

●Cancer Care Ontario (CCO): Position statement on prostate cancer screening using the prostate-specific antigen (PSA) test (2017)

●Canadian Task Force on Preventive Health Care (CTFPHC): Recommendations on screening for prostate cancer with the prostate-specific antigen test (2014)

United States

●National Cancer Institute (NCI): Prostate cancer – Health professional version

●American Urological Association (AUA)/Society of Urologic Oncology (SUO): Guideline on early detection of prostate cancer (2023)

●AUA: Early detection of prostate cancer – Guideline (2013, reviewed 2018)

●US Preventive Services Task Force (USPSTF): Final recommendation statement on prostate cancer – Screening (2018)

●American Cancer Society (ACS): Guideline for the early detection of prostate cancer, update (2010)

Europe

●European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG): Guidelines on prostate cancer (2024)

●European Society for Medical Oncology (ESMO): Clinical practice guideline for treatment recommendations for prostate cancer – Considering treatment intensification and use of novel systemic agents, update (2023)

•ESMO: Cancer of the prostate – Clinical practice guidelines for diagnosis, treatment, and follow-up (2020)

●ESMO: Prostate cancer – Consensus conference guidelines, 2012 (published 2013)

United Kingdom

●Prostate Cancer UK: Interim position on the PSA blood test in asymptomatic men (2022)

●Choosing Wisely UK: Royal College of Pathologists – Unless a patient is at increased risk of prostate cancer because of race or family history, PSA testing does not necessarily lead to a longer life (2016)

Australia–New Zealand

●Choosing Wisely Australia: Do not perform PSA testing for prostate cancer screening in men with no symptoms and whose life expectancy is less than 7 years (2022)

●Royal Australian College of General Practitioners (RACGP): Guidelines for Preventive Activities in General Practice (Red Book) – Prostate cancer, 9th edition (2021)

●Australian National Health and Medical Research Council (NHMRC): Prostate-specific antigen (PSA) testing in asymptomatic men (2014)

Japan

●[In Japanese] Choosing Wisely Japan: PSA examination for prostate cancer – When necessary and when not necessary for men (2018)

●[In Japanese] Japanese Urological Association (JUA): Screening guideline for prostate cancer (2018)

●[In English] JUA: Evidence-based clinical practice guideline for prostate cancer, 2016 edition (published 2017)

●[In Japanese] JUA: Clinical practice guideline for prostate cancer (2016)